Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment

Yong Wang, Pratap Challa, David L. Epstein, Fan Yuan

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Ethacrynic acid (ECA) is a potential glaucoma drug that can reduce intraocular pressure. However, conventional methods of ECA administration may cause toxicity to normal eye tissues and are inconvenient to patients. Therefore, we developed and characterized an ECA loaded poly(lactide-co- glycolide) (PLGA) copolymer film, and quantified the therapeutic efficacy of the film implanted in the rabbit eye. In the aqueous medium, the release of ECA from the PLGA50:50 film was time dependent and more than 90% of ECA was released within a week. This release profile was consistent with the kinetics of water uptake and microstructural changes of PLGA50:50 films as revealed by an electron microscopy examination. ECA release and PLGA degradation caused a gradual pH decrease in the release medium. The total pH decrease was 0.4 unit in 3 days. We also observed that the initial rate of ECA release was positively correlated with the weight ratio of ECA versus PLGA and inversely correlated with the molar ratio of lactide versus glycolide in PLGA films. At the end of a 3-day incubation, the cumulative release of ECA from PLGA50:50, PLGA85:15 and PLGA100:00 films were 78.8%, 9.35% and 3.60%, respectively. When the PLGA50:50 film loaded with ECA was implanted into the sclera of rabbit eyes, the intraocular pressure was significantly reduced and the reduction was maintained for at least 10 days. These data indicate that PLGA films have a potential to be used as a controlled ECA release device for glaucoma treatment.

Original languageEnglish (US)
Pages (from-to)4279-4285
Number of pages7
JournalBiomaterials
Volume25
Issue number18
DOIs
StatePublished - Aug 1 2004

Fingerprint

Ethacrynic Acid
Polyglactin 910
Glaucoma
Acids
Therapeutics
Intraocular Pressure
Rabbits
Sclera
Electron microscopy
Toxicity
Electron Microscopy
Copolymers

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Wang, Yong ; Challa, Pratap ; Epstein, David L. ; Yuan, Fan. / Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment. In: Biomaterials. 2004 ; Vol. 25, No. 18. pp. 4279-4285.
@article{6056c294254c43a5b01f94dd8d24a5c7,
title = "Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment",
abstract = "Ethacrynic acid (ECA) is a potential glaucoma drug that can reduce intraocular pressure. However, conventional methods of ECA administration may cause toxicity to normal eye tissues and are inconvenient to patients. Therefore, we developed and characterized an ECA loaded poly(lactide-co- glycolide) (PLGA) copolymer film, and quantified the therapeutic efficacy of the film implanted in the rabbit eye. In the aqueous medium, the release of ECA from the PLGA50:50 film was time dependent and more than 90{\%} of ECA was released within a week. This release profile was consistent with the kinetics of water uptake and microstructural changes of PLGA50:50 films as revealed by an electron microscopy examination. ECA release and PLGA degradation caused a gradual pH decrease in the release medium. The total pH decrease was 0.4 unit in 3 days. We also observed that the initial rate of ECA release was positively correlated with the weight ratio of ECA versus PLGA and inversely correlated with the molar ratio of lactide versus glycolide in PLGA films. At the end of a 3-day incubation, the cumulative release of ECA from PLGA50:50, PLGA85:15 and PLGA100:00 films were 78.8{\%}, 9.35{\%} and 3.60{\%}, respectively. When the PLGA50:50 film loaded with ECA was implanted into the sclera of rabbit eyes, the intraocular pressure was significantly reduced and the reduction was maintained for at least 10 days. These data indicate that PLGA films have a potential to be used as a controlled ECA release device for glaucoma treatment.",
author = "Yong Wang and Pratap Challa and Epstein, {David L.} and Fan Yuan",
year = "2004",
month = "8",
day = "1",
doi = "10.1016/j.biomaterials.2003.10.075",
language = "English (US)",
volume = "25",
pages = "4279--4285",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "18",

}

Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment. / Wang, Yong; Challa, Pratap; Epstein, David L.; Yuan, Fan.

In: Biomaterials, Vol. 25, No. 18, 01.08.2004, p. 4279-4285.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment

AU - Wang, Yong

AU - Challa, Pratap

AU - Epstein, David L.

AU - Yuan, Fan

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Ethacrynic acid (ECA) is a potential glaucoma drug that can reduce intraocular pressure. However, conventional methods of ECA administration may cause toxicity to normal eye tissues and are inconvenient to patients. Therefore, we developed and characterized an ECA loaded poly(lactide-co- glycolide) (PLGA) copolymer film, and quantified the therapeutic efficacy of the film implanted in the rabbit eye. In the aqueous medium, the release of ECA from the PLGA50:50 film was time dependent and more than 90% of ECA was released within a week. This release profile was consistent with the kinetics of water uptake and microstructural changes of PLGA50:50 films as revealed by an electron microscopy examination. ECA release and PLGA degradation caused a gradual pH decrease in the release medium. The total pH decrease was 0.4 unit in 3 days. We also observed that the initial rate of ECA release was positively correlated with the weight ratio of ECA versus PLGA and inversely correlated with the molar ratio of lactide versus glycolide in PLGA films. At the end of a 3-day incubation, the cumulative release of ECA from PLGA50:50, PLGA85:15 and PLGA100:00 films were 78.8%, 9.35% and 3.60%, respectively. When the PLGA50:50 film loaded with ECA was implanted into the sclera of rabbit eyes, the intraocular pressure was significantly reduced and the reduction was maintained for at least 10 days. These data indicate that PLGA films have a potential to be used as a controlled ECA release device for glaucoma treatment.

AB - Ethacrynic acid (ECA) is a potential glaucoma drug that can reduce intraocular pressure. However, conventional methods of ECA administration may cause toxicity to normal eye tissues and are inconvenient to patients. Therefore, we developed and characterized an ECA loaded poly(lactide-co- glycolide) (PLGA) copolymer film, and quantified the therapeutic efficacy of the film implanted in the rabbit eye. In the aqueous medium, the release of ECA from the PLGA50:50 film was time dependent and more than 90% of ECA was released within a week. This release profile was consistent with the kinetics of water uptake and microstructural changes of PLGA50:50 films as revealed by an electron microscopy examination. ECA release and PLGA degradation caused a gradual pH decrease in the release medium. The total pH decrease was 0.4 unit in 3 days. We also observed that the initial rate of ECA release was positively correlated with the weight ratio of ECA versus PLGA and inversely correlated with the molar ratio of lactide versus glycolide in PLGA films. At the end of a 3-day incubation, the cumulative release of ECA from PLGA50:50, PLGA85:15 and PLGA100:00 films were 78.8%, 9.35% and 3.60%, respectively. When the PLGA50:50 film loaded with ECA was implanted into the sclera of rabbit eyes, the intraocular pressure was significantly reduced and the reduction was maintained for at least 10 days. These data indicate that PLGA films have a potential to be used as a controlled ECA release device for glaucoma treatment.

UR - http://www.scopus.com/inward/record.url?scp=1642330598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642330598&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2003.10.075

DO - 10.1016/j.biomaterials.2003.10.075

M3 - Article

C2 - 15046918

AN - SCOPUS:1642330598

VL - 25

SP - 4279

EP - 4285

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 18

ER -